Tags

Type your tag names separated by a space and hit enter

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Abstract

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis.

OBJECTIVE

To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis.

DESIGN

A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1·8 mg od.

RESULTS

Nineteen women with PCOS and 17 controls were recruited, age 32·8 ± 7·2 vs 33·5 ± 6·7 years and weight 100·9 ± 16·7 vs 99·3 ± 14·7 kg, respectively. At baseline, the PCOS group had higher testosterone 1·2 ± 0·3 vs 0·9 ± 0·3 nm (P = 0·01), HOMA-IR 5·1 ± 2·6 vs 3·5 ± 1·3 (P = 0·03), AST 22·4 ± 5·2 vs 18·8 ± 3·4 u/l (P = 0·04), PIIINP 4·4 ± 0·8 vs 3·5 ± 0·8 ug/ml (P = 0·01) and NAFLD seven (35%) vs none (P = 0·005), respectively. Twenty-five (69%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3·0 ± 4·2 kg (P = 0·01) and 3·8 ± 3·4 kg (P = 0·001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4·4 ± 0·8 vs 3·7 ± 0·9 ug/ml (P < 0·01), but not in controls 3·5 ± 0·8 vs 3·2 ± 0·7 ug/ml (P = 0·08).

CONCLUSIONS

Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Academic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK; Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK.

    , , , ,

    Source

    Clinical endocrinology 81:4 2014 Oct pg 523-8

    MeSH

    Adult
    Case-Control Studies
    Female
    Glucagon-Like Peptide 1
    Humans
    Liraglutide
    Liver Cirrhosis
    Non-alcoholic Fatty Liver Disease
    Obesity
    Polycystic Ovary Syndrome
    Triglycerides

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    24256515

    Citation

    Kahal, H, et al. "Glucagon-like Peptide-1 Analogue, Liraglutide, Improves Liver Fibrosis Markers in Obese Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease." Clinical Endocrinology, vol. 81, no. 4, 2014, pp. 523-8.
    Kahal H, Abouda G, Rigby AS, et al. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2014;81(4):523-8.
    Kahal, H., Abouda, G., Rigby, A. S., Coady, A. M., Kilpatrick, E. S., & Atkin, S. L. (2014). Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clinical Endocrinology, 81(4), pp. 523-8. doi:10.1111/cen.12369.
    Kahal H, et al. Glucagon-like Peptide-1 Analogue, Liraglutide, Improves Liver Fibrosis Markers in Obese Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease. Clin Endocrinol (Oxf). 2014;81(4):523-8. PubMed PMID: 24256515.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. AU - Kahal,H, AU - Abouda,G, AU - Rigby,A S, AU - Coady,A M, AU - Kilpatrick,E S, AU - Atkin,S L, Y1 - 2013/12/12/ PY - 2013/08/17/received PY - 2013/09/14/revised PY - 2013/10/13/revised PY - 2013/11/16/accepted PY - 2013/11/22/entrez PY - 2013/11/22/pubmed PY - 2015/5/16/medline SP - 523 EP - 8 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 81 IS - 4 N2 - INTRODUCTION: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an independent predictor of liver cirrhosis. OBJECTIVE: To assess whether 6-month treatment with GLP-1 analogue, liraglutide, improves markers of liver fibrosis. DESIGN: A case-control study comparing women with PCOS to age- and weight-matched controls. PCOS was diagnosed according to the Rotterdam criteria. All participants underwent liver function tests and liver ultrasound scan to assess for fatty infiltration. Serum marker for liver fibrosis, PIIINP, was measured at baseline and after 6-month treatment with liraglutide 1·8 mg od. RESULTS: Nineteen women with PCOS and 17 controls were recruited, age 32·8 ± 7·2 vs 33·5 ± 6·7 years and weight 100·9 ± 16·7 vs 99·3 ± 14·7 kg, respectively. At baseline, the PCOS group had higher testosterone 1·2 ± 0·3 vs 0·9 ± 0·3 nm (P = 0·01), HOMA-IR 5·1 ± 2·6 vs 3·5 ± 1·3 (P = 0·03), AST 22·4 ± 5·2 vs 18·8 ± 3·4 u/l (P = 0·04), PIIINP 4·4 ± 0·8 vs 3·5 ± 0·8 ug/ml (P = 0·01) and NAFLD seven (35%) vs none (P = 0·005), respectively. Twenty-five (69%) participants completed the study (13 PCOS, 12 controls). Following treatment, weight was reduced by 3·0 ± 4·2 kg (P = 0·01) and 3·8 ± 3·4 kg (P = 0·001), respectively. Similarly, HOMA-IR, hsCRP, triglycerides and urinary isoprostane significantly reduced in both groups. PIIINP significantly reduced the in PCOS group 4·4 ± 0·8 vs 3·7 ± 0·9 ug/ml (P < 0·01), but not in controls 3·5 ± 0·8 vs 3·2 ± 0·7 ug/ml (P = 0·08). CONCLUSIONS: Treatment with liraglutide, and/or associated weight loss, significantly reduced PIIINP levels in obese women with PCOS. This may be an additional beneficial factor when considering the use of liraglutide in women with PCOS, obesity and NAFLD. SN - 1365-2265 UR - https://www.unboundmedicine.com/medline/citation/24256515/Glucagon_like_peptide_1_analogue_liraglutide_improves_liver_fibrosis_markers_in_obese_women_with_polycystic_ovary_syndrome_and_nonalcoholic_fatty_liver_disease_ L2 - https://doi.org/10.1111/cen.12369 DB - PRIME DP - Unbound Medicine ER -